Cancer Treatment Abroad: When It's Worth Considering and How to Do It Safely

When International Cancer Treatment Makes Sense

Seeking cancer treatment abroad is not about medical tourism or distrusting UK oncology, which is among the best in the world. It makes sense in specific circumstances: when a treatment approved in other countries is not yet available in the UK (regulatory timelines differ between the MHRA, FDA, and EMA), when clinical trial access for your specific cancer type is available abroad but not domestically, when the volume of your specific procedure is higher at an international centre (for rare cancers, the world's highest-volume centres may be outside the UK), or when waiting times for time-sensitive treatment are unacceptable. It does not make sense to seek standard chemotherapy or radiotherapy abroad, the UK delivers these to international standards through established NHS cancer centres.

Proton Beam Therapy: Who Actually Benefits

Proton beam therapy delivers radiation with greater precision than conventional photon radiotherapy, reducing damage to surrounding healthy tissue. The NHS funds proton beam therapy abroad (primarily at centres in the US, Switzerland, and Germany) for specific indications where clinical benefit is established, principally certain childhood cancers and skull-base tumours. Two NHS proton beam centres now operate in the UK: The Christie in Manchester and University College London Hospitals. For adult cancers, the evidence for proton beam superiority is established for a narrow range of tumours. For most common adult cancers (breast, lung, prostate, bowel), conventional radiotherapy achieves equivalent outcomes. Private proton beam therapy costs $30,000–150,000 depending on the treatment site and centre. Before pursuing this, request a clinical opinion from a UK radiation oncologist on whether proton therapy would offer meaningful benefit for your specific case.

Immunotherapy and Targeted Therapy: Access and Costs

The UK sometimes lags behind the US and EU in approving new cancer drugs. A treatment approved by the FDA in January may not receive NICE approval until 12–18 months later. The Cancer Drugs Fund (CDF) provides early access to some drugs pending full NICE evaluation, but not all. If a drug is available abroad but not in the UK, options include: accessing the drug through the CDF (if listed), participation in a clinical trial (check clinicaltrials.gov and the NIHR Be Part of Research portal), compassionate use or expanded access programmes (the pharmaceutical company may provide the drug outside trials, your oncologist can request this), or self-funding treatment abroad. Immunotherapy drugs like pembrolizumab (Keytruda) and nivolumab (Opdivo) cost approximately £6,000–8,000 per cycle, with treatment courses typically 6–24 months. CAR-T cell therapy, approved in the UK for certain blood cancers, costs approximately £280,000–370,000 per treatment.

Evaluating International Cancer Centres

If you decide to explore treatment abroad, assess centres using objective criteria: is the centre accredited by JCI (Joint Commission International) or equivalent national body? What is the centre's case volume for your specific cancer type? Does the centre participate in international clinical trial networks? What are the published outcomes (survival rates, complication rates) for your specific treatment? Is there a dedicated international patient department with English-speaking coordinators? What is the centre's MDT process? Will the treating oncologist communicate directly with your UK team? Established international cancer centres include: Memorial Sloan Kettering and MD Anderson (US), Gustave Roussy (France), Charité (Germany), Karolinska (Sweden), and Sheba Medical Centre (Israel). For an independent evaluation of whether international treatment is appropriate for your case, a UK-based oncology second opinion is an essential first step.

Logistics: What You Need to Plan

Practical considerations for treatment abroad: medical visa requirements vary by country (the US requires a B-2 visa for medical treatment), flights should be booked with medical insurance and flexibility for schedule changes, accommodation near the hospital for the treatment duration plus recovery period, a companion who can advocate for you if you are unwell, translation of all medical records into the language of the treating centre (certified medical translators are available for £50–150 per page), ensure your travel insurance explicitly covers the medical condition being treated and potential complications (standard travel insurance excludes pre-existing conditions), and plan for continuity of care on return, your UK oncologist must be briefed on all treatment received and agree to ongoing monitoring and follow-up.

NHS Funding for Overseas Treatment

In certain circumstances, the NHS will fund treatment abroad. The S2 route (formerly E112) allows NHS patients to receive treatment in EU/EEA countries where the treatment is part of the NHS basket of care but waiting times are unacceptable. The process requires: your treating NHS consultant to confirm the treatment is clinically necessary, the treatment to be available within the NHS but subject to undue delay, and approval from the Overseas Healthcare Team at NHS England. For treatments not available in the UK, an Individual Funding Request (IFR) can be submitted by your consultant arguing for 'exceptionality', that your case differs from the general population in a way that justifies NHS funding. IFR success rates are low (approximately 20–30%), but for genuine cases of exceptional clinical need, this route is worth pursuing with specialist support.